← Product Code [NRY](/productcode/NRY) · K262391

# APRO 35 Swift Catheter and Alembic Aspiration Tubing (K262391)

_Alembic, LLC · NRY · Aug 12, 2026 · Cardiovascular · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K262391

## Device Facts

- **Applicant:** Alembic, LLC
- **Product Code:** [NRY](/productcode/NRY.md)
- **Decision Date:** Aug 12, 2026
- **Decision:** SESE
- **Submission Type:** Special
- **Regulation:** 21 CFR 870.1250
- **Device Class:** Class 2
- **Review Panel:** Cardiovascular
- **Attributes:** Therapeutic

## Indications for Use

The APRO® 35 Swift Catheter with an aspiration pump and the Alembic Aspiration Tubing is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment. The Alembic Aspiration Tubing is intended to connect the APRO® 35 Swift Catheter to the aspiration pump.

## Device Story

Single-lumen, braid/coil-reinforced catheter; removes thrombus via aspiration. Input: suction from external pump; guided over neurovascular guidewire under fluoroscopy to occlusion site. Output: thrombus removal. Used in neurovascular procedures by physicians; distal shaft features hydrophilic coating and radiopaque marker for visualization. Connects to aspiration pump via Alembic Aspiration Tubing. Clinical benefit: revascularization of occluded intracranial vessels in acute ischemic stroke patients.

## Clinical Evidence

No clinical data. Substantial equivalence established via non-clinical bench testing, including visual/dimensional inspection, particulate testing, vacuum integrity, kink resistance, hub leakage, torque strength, burst pressure, tensile strength, delivery/retrieval force, 3-point bend, and simulated use clot retrieval in anatomical models. Biocompatibility assessed per ISO 10993-1.

## Technological Characteristics

Single-lumen catheter; materials: Nylon hub, cyanoacrylate adhesive, Santoprene strain relief, PTFE/Pebax liner, 304V stainless steel braid/coil, platinum/iridium marker band, hydrophilic coating. Dimensions: 0.049" proximal OD, 0.047" distal OD, 0.035" ID. Sterilization: Ethylene Oxide. Connectivity: Connects to external aspiration pump via tubing. Standards: ISO 10555-1, ISO 80369-7, ISO 11135, ISO 10993-1.

## Regulatory Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

## Predicate Devices

- APRO® 45 Catheter and Alembic Aspiration Tubing ([K251015](/device/K251015.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

**FDA** U.S. FOOD & DRUG
ADMINISTRATION

August 12, 2026

Alembic, LLC
Stina Almaleh
Senior Regulatory and Quality Assurance Engineer
627 National Avenue
Mountain View, California 94043

Re: K262391

Trade/Device Name: APRO 35 Swift Catheter and Alembic Aspiration Tubing
Regulation Number: 21 CFR 870.1250
Regulation Name: Percutaneous Catheter
Regulatory Class: Class II
Product Code: NRY
Dated: July 13, 2026
Received: July 14, 2026

Dear Stina Almaleh:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K262391 - Stina Almaleh

Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

{2}

K262391 - Stina Almaleh

Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# NAIRA MURADYAN -S

Naira Muradyan, PhD

Assistant Director

DHT5A: Division of Neurosurgical,

Neurointerventional, and

Neurodiagnostic Devices

OHT5: Office of Neurological and

Physical Medicine Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

{3}

|  Indications for Use  |   |   |
| --- | --- | --- |
|  Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K262391 | ?  |
|  Please provide the device trade name(s). |   | ?  |
|  APRO® 35 Swift Catheter and Alembic Aspiration Tubing  |   |   |
|  Please provide your Indications for Use below. |   | ?  |
|  The APRO® 35 Swift Catheter with an aspiration pump and the Alembic Aspiration Tubing is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment.The Alembic Aspiration Tubing is intended to connect the APRO® 35 Swift Catheter to the aspiration pump.  |   |   |
|  Please select the types of uses. | Prescription Use (21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C) | ?  |
|  Please select the age group(s) for which the device(s) is to be used. | Neonates/Newborns (Birth to < 29 days old)Infants (29 days old to < 2 years old)Children (2 years old to < 12 years old)Adolescents (12 years old to < 22 years old)Adults (22 years old and greater) | ?  |

{4}

510(k) Number: K262391

ALEMBIC

# 510(K) SUMMARY

This 510(k) Summary is provided in accordance with the requirements of 21 CFR §807.92.

### 1) Submitter Information

**Submitter:** Alembic, LLC  
627 National Ave.  
Mountain View, CA 94043**Contact:** Stina Almaleh  
Senior Regulatory and Quality Assurance Engineer  
Email: salmaleh@alembicllc.com  
Telephone Number: (650) 388-5238**Date Prepared:** August 08, 2026

### 2) Device Name and Classification

**Trade/Proprietary Name:** APRO® 35 Swift Catheter and Alembic Aspiration Tubing**Common Name:** Catheter, Thrombus Retriever**Classification Name:** Percutaneous Catheter, 21 CFR 870.1250**Regulatory Class:** Class II**Product Codes:** NRY**Review Panel:** Neurology

### 3) Legally Marketed Predicate Device

**Predicate Device:** K251015 APRO® 45 Catheter and Alembic Aspiration Tubing

### 4) Device Description

The APRO® 35 Swift Catheter is a single-lumen, braid and coil reinforced catheter. The APRO® 35 Swift Catheter is designed to remove thrombus from the vasculature using aspiration. The APRO® 35 Swift Catheter targets aspiration from a suction pump directly to the thrombus to remove thrombus from an occluded vessel. The APRO® 35 Swift Catheter is introduced through a guide catheter or long femoral sheath and into the intracranial vasculature and guided over a neurovascular guidewire under fluoroscopic visualization to the site of the primary occlusion. The distal shaft has a hydrophilic coating to aid navigation through the vasculature. A radiopaque marker is located at the distal end of the catheter for visualization under fluoroscopy. For the aspiration source, the APRO® 35 Swift Catheter is used in conjunction with an aspiration pump with pre-specified performance parameters that is connected using the Alembic Aspiration Tubing, along with a legally marketed canister and accessories kit. The APRO® 35 Swift Catheter is available in lengths of 125, 146, and 160 cm and is provided with an introducer sheath. The APRO® 35 Swift Catheter contains animal derived materials made from tallow derivatives.

The Alembic Aspiration Tubing connects the APRO® 35 Swift Catheter to the aspiration

Page 1 of 6

APRO® 35 Swift Catheter and Alembic Aspiration Tubing

{5}

510(k) Number: K262391

ALEMBIC

pump. The flow control valve allows control of the aspiration flow using an ON/OFF switch. It is available in one size.

# 5) Indications for Use

The APRO® 35 Swift Catheter with an aspiration pump and the Alembic Aspiration Tubing is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment.

The Alembic Aspiration Tubing is intended to connect the APRO® 35 Swift Catheter to the aspiration pump.

# 6) Technological Characteristics Comparison

Alembic has demonstrated that the APRO® 35 Swift Catheter and Alembic Aspiration Tubing are substantially equivalent to the predicate device APRO® 45 Catheter and Alembic Aspiration Tubing based on the similarity in materials, similarity in design concept, and the same fundamental operating principles. A comparison of the APRO® 35 Swift Catheter with the predicate is summarized in Table 1 below. There are no changes to the Alembic Aspiration Tubing compared to that included as part of the K251015 submission.

Table 1. APRO® 35 Swift Catheter and Alembic Aspiration Tubing Comparison with the Predicate Device

|  Category | Subject Device APRO® 35 Swift Catheter and Alembic Aspiration Tubing | Predicate Device APRO® 45 Catheter and Alembic Aspiration Tubing  |
| --- | --- | --- |
|  510(k) Number | K262391 | K251015  |
|  Regulatory Class | Same as predicate. | Class II, 21 CFR 870.1250, NRY  |
|  Indications for Use | The APRO® 35 Swift Catheter with an aspiration pump and the Alembic Aspiration Tubing is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment. The Alembic Aspiration Tubing is intended to connect the APRO® 35 Swift Catheter to the aspiration pump. | The APRO® 45 Catheter with an aspiration pump and the Alembic Aspiration Tubing is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for thrombolytic drug therapy or who failed thrombolytic drug therapy are candidates for treatment. The Alembic Aspiration Tubing is intended to connect the APRO® 45 Catheter to the aspiration pump.  |

Page 2 of 6

APRO® 35 Swift Catheter and Alembic Aspiration Tubing

{6}

510(k) Number: K262391

ALEMBIC

Table 1. APRO® 35 Swift Catheter and Alembic Aspiration Tubing Comparison with the Predicate Device

|  Category | Subject Device APRO® 35 Swift Catheter and Alembic Aspiration Tubing | Predicate Device APRO® 45 Catheter and Alembic Aspiration Tubing  |
| --- | --- | --- |
|  Principles of Operation | **Same as predicate.** | Using conventional catheterization techniques under fluoroscopic guidance, the catheter is advanced into the target vessel over an appropriate neurovascular guidewire. The catheter is positioned proximal to the thrombus to aspirate.  |
|  **Materials**  |   |   |
|  Hub | **Same as predicate.** | Nylon  |
|  Adhesive | **Same as predicate.** | Cyanoacrylate  |
|  Strain Relief | **Same as predicate.** | Santoprene (thermoplastic elastomer)  |
|  Liner | **Same as predicate.** | Polytetrafluoroethylene (PTFE)/Pebax composite  |
|  Shaft Coil or Braid | **Same as predicate.** | 304V stainless steel braid 304V stainless steel coil  |
|  Extrusions | **Same as predicate.** | Polyether block amide  |
|  Marker Band | **Same as predicate.** | Platinum/ iridium  |
|  Coating | **Same as predicate.** | Hydrophilic coating  |
|  **Dimensions**  |   |   |
|  Proximal Outer Diameter | 0.049 inch | 0.060 inch  |
|  Distal Outer Diameter | 0.047 inch | 0.058 inch  |
|  Inner Diameter | 0.035 inch | 0.045 inch  |
|  Effective Lengths | 125, 146, 160 cm | 115, 125, 146, 160 cm  |
|  Coated Length | 90 cm | 60 cm  |
|  Tip Shape | **Same as predicate.** | Straight  |
|  **Accessories**  |   |   |
|  Introducer Sheath | **Same as predicate.** | Yes  |
|  **Packaging Materials**  |   |   |
|  Pouch | **Same as predicate.** | Nylon/Polyethylene/Tyvek  |
|  Packaging Hoop Coil | **Same as predicate.** | Polyethylene  |
|  Packaging Card | **Same as predicate.** | Polyethylene  |
|  Shelf Carton | **Same as predicate.** | Solid bleached sulfate paperboard  |
|  **Other**  |   |   |
|  Sterilization | **Same as predicate.** | Ethylene Oxide  |
|  Shelf Life | **Same as predicate.** | 1 year  |
|  Use Conditions | **Same as predicate.** | Sterile, single use, disposable  |
|  **Alembic Aspiration Tubing**  |   |   |
|  Aspiration Tubing | **Same as predicate.** | 110-inch length Tubing ID = 0.110 inch  |

### 7) Performance Data

Alembic performed non-clinical bench, sterility, shelf-life, and biocompatibility testing. The

Page 3 of 6

APRO® 35 Swift Catheter and Alembic Aspiration Tubing

{7}

510(k) Number: K262391

ALEMBIC

results demonstrate substantial equivalence of the subject APRO® 35 Swift Catheter and Alembic Aspiration Tubing to the legally marketed predicate device.

### A. Design Verification Testing – Non-Clinical Bench

Bench performance testing was conducted to support the APRO® 35 Swift Catheter submission. The results of the design verification and validation testing confirm that the APRO® 35 Swift Catheter conforms to the predefined specifications and performs as intended. Included in **Table 2** is a description of bench performance tests that were conducted to support substantial equivalence determination.

**Table 2. Summary of Non-Clinical Bench Test Results**

|  Test | Acceptance Criteria | Conclusion  |
| --- | --- | --- |
|  Visual and Dimensional Characteristics | Catheter meets the visual and dimensional specifications. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|   |  Introducer Sheath meets the visual and dimensional specifications. | The Introducer Sheath met the acceptance criteria.  |
|  Particulate | Catheter meets the acceptance criteria. Subject device was evaluated with a predicate device under the same test conditions. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Vacuum Integrity | Catheter is free from collapse. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Kink Resistance | Catheter shaft shall not kink at clinically relevant radii. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Catheter Hub Leakage | Catheter does not leak air into hub assembly with methods specified in ISO 10555-1, Annex D. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Hub Compatibility | Catheter meets the requirements specified in ISO 80369-7. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Catheter Torque Strength | Catheter must withstand the minimum required number of rotations without breakage and without kinking compared to legally marketed devices. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Dynamic Burst Pressure | No damage to catheter with dynamic pressure. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Liquid Leakage | Catheter must withstand pressure with methods specified in ISO 10555-1, Annex C. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Static Burst | Catheter must withstand pressures anticipated for clinical use. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Tensile Strength of Catheter Hub and Shaft | Catheter hub and shaft must meet tensile strength specification. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Tensile Strength of Catheter Tip | Catheter tip must meet tip tensile strength specification. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Delivery and Retrieval Force | Catheter delivery and retrieval force must be acceptable. Forces were compared to a predicate. | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  3-Point Bend | Catheter 3-Point Bend force must be acceptable. Forces were compared to a predicate | The APRO® 35 Swift Catheter met the acceptance criteria.  |
|  Simulated Use including Clot Retrieval | When used per the Instructions for Use with accessory devices in an anatomical neurovascular | The APRO® 35 Swift Catheter and Alembic Aspiration Tubing  |

Page 4 of 6

APRO® 35 Swift Catheter and Alembic Aspiration Tubing

{8}

510(k) Number: K262391

ALEMBIC

Table 2. Summary of Non-Clinical Bench Test Results

|  Test | Acceptance Criteria | Conclusion  |
| --- | --- | --- |
|   | model, the Catheter and Aspiration Tubing must meet functionality specifications. Clot retrieval from various locations of the anatomical model was performed using the subject device system. | met the acceptance criteria.  |
|  Corrosion Resistance | Catheter shall show no signs of corrosion when tested in accordance with ISO 10555-1, Annex A. | The APRO® 35 Swift Catheter met the acceptance criteria.  |

### B. Design Verification Testing – Animal

Substantial equivalence was established based on non-clinical bench performance data. Animal testing data were not deemed necessary.

### C. Sterilization and Shelf-Life

The APRO® 35 Swift Catheter and Alembic Aspiration Tubing are sterilized using an ethylene oxide sterilization cycle that was verified to a sterility assurance level of 1x10⁻⁶ in accordance with ISO 11135. Aging studies for the APRO® 35 Swift Catheter and Alembic Aspiration Tubing have established that the subject device and packaging remain functional for the labeled expiration date. Aging studies for packaging integrity, seal strength, and the device functionality were performed and met the acceptance criteria.

### D. Biocompatibility

Biological safety evaluation was conducted for the APRO® 35 Swift Catheter in accordance with ISO 10993-1 and the FDA Guidance, “Use of International Standard ISO 10993-1, “Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process”.”

Additionally, the risk management process determined that the biocompatibility testing conducted on the predicate device APRO® 45 Catheter (K251015) per ISO 10993-1 and applicable regulatory requirements, adequately assesses the biocompatibility profile of the subject APRO® 35 Swift Catheter for endpoints recommended by the FDA biocompatibility guidance for an externally communicating device with limited (≤24 hours) duration of contact with circulating blood. Additionally, a comparative assessment of the subject APRO® 35 Swift Catheter and predicate APRO® 45 Catheter did not identify any significant differences in the surface characteristics or geometry of these devices as summarized in Table 3.

Page 5 of 6

APRO® 35 Swift Catheter and Alembic Aspiration Tubing

{9}

510(k) Number: K262391

ALEMBIC

Table 3. Summary of Biocompatibility Test Results

|  Test | Results | Conclusions  |
| --- | --- | --- |
|  Thrombogenicity – Comparative Surface and Geometry Assessment | Comparative surface assessment using 40x optical microscopy at representative locations of the subject device and the predicate device did not find any differences in the roughness or presence of any defects. The subject device has similar surface morphology as the predicate device APRO® 45 Catheter. | Non-thrombogenic.  |

# E. Clinical Testing

Substantial equivalence was established based on non-clinical performance data. Human clinical data were not deemed necessary.

# 8) Conclusion

Based on the comparison of the technological characteristics and the non-clinical testing, the subject device is found to be substantially equivalent to the predicate device. The differences in technological characteristics do not raise new questions of safety and effectiveness. Testing was conducted to demonstrate that the subject device meets the specifications and performs as intended.

Page 6 of 6

APRO® 35 Swift Catheter and Alembic Aspiration Tubing

---

**Source:** [https://fda.innolitics.com/device/K262391](https://fda.innolitics.com/device/K262391)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com